SG10201803778PA - Treatment for rheumatoid arthritis - Google Patents

Treatment for rheumatoid arthritis

Info

Publication number
SG10201803778PA
SG10201803778PA SG10201803778PA SG10201803778PA SG10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA
Authority
SG
Singapore
Prior art keywords
rheumatoid arthritis
treatment
csf antibodies
mor103
dosages
Prior art date
Application number
SG10201803778PA
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of SG10201803778PA publication Critical patent/SG10201803778PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

TREATMENT FOR RHEUMATOID ARTHRITIS The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting. Figure 2
SG10201803778PA 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis SG10201803778PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
SG10201803778PA true SG10201803778PA (en) 2018-06-28

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803778PA SG10201803778PA (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis
SG11201501595YA SG11201501595YA (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201501595YA SG11201501595YA (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Country Status (23)

Country Link
US (3) US20150246969A1 (en)
EP (3) EP3345923A1 (en)
JP (3) JP2015533806A (en)
KR (3) KR20150056846A (en)
CN (2) CN109999195A (en)
AU (2) AU2013320261A1 (en)
BR (1) BR112015006189B1 (en)
CA (1) CA2884124A1 (en)
CL (2) CL2015000696A1 (en)
CR (1) CR20150153A (en)
DO (1) DOP2015000070A (en)
EA (1) EA031489B1 (en)
HK (1) HK1208231A1 (en)
IL (1) IL237554B (en)
IN (1) IN2015KN00657A (en)
MA (1) MA37946B1 (en)
MX (2) MX2015003644A (en)
MY (1) MY175388A (en)
PE (1) PE20151079A1 (en)
PH (1) PH12015500591A1 (en)
SG (2) SG10201803778PA (en)
UA (1) UA117228C2 (en)
WO (1) WO2014044768A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37946B1 (en) * 2012-09-20 2018-09-28 Morphosys Ag Use of an anti-gm-csf antibody for the treatment of rheumatoid arthritis
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
WO2015169742A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
JP7281795B2 (en) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー Compositions and methods for treating pancreatitis and pain with death receptor agonists
JP7256116B2 (en) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド ANTI-GM-CSF ANTIBODY AND USES THEREOF
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100408229B1 (en) 1996-10-04 2003-12-01 암겐 인코포레이티드 Pharmaceutical compositions containing an mpl ligand
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ES2527428T3 (en) * 2005-05-18 2015-01-23 Morphosys Ag Anti-GM-CSF antibodies and uses thereof
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
EP2402013A1 (en) * 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
JP5456658B2 (en) * 2007-03-30 2014-04-02 メディミューン，エルエルシー Antibody preparation
JP2010527325A (en) * 2007-04-02 2010-08-12 ジェネンテック， インコーポレイテッド Biomarkers that predict rheumatoid arthritis in response to B cell antagonists
DE602008004235D1 (en) 2007-04-05 2011-02-10 Sandoz Ag STABLE Aqueous G-CSF FORMULATIONS
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
KR20100102108A (en) 2007-11-13 2010-09-20 에베크 인코포레이티드 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2009329811B2 (en) * 2008-12-22 2016-02-25 The University Of Melbourne Pain treatment
WO2010071924A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Osteoarthritis treatment
JP2010241718A (en) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd Stable aqueous solution preparation of antibody
RU2539034C2 (en) * 2009-05-05 2015-01-10 МорфоСис АГ Method of treating multiple sclerosis
SI2341061T1 (en) 2009-12-31 2013-12-31 Arven Ilac Sanayi Ve Ticaret A.S. A novel process for preparing G-CSF (granulocyte colony stimulating factor)
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
RU2013156435A (en) 2011-07-06 2015-08-20 МорфоСис АГ THERAPEUTIC COMBINATIONS ANTI-CD20 AND ANTI-GM-CSF ANTIBODIES AND THEIR APPLICATIONS
MA37946B1 (en) * 2012-09-20 2018-09-28 Morphosys Ag Use of an anti-gm-csf antibody for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
BR112015006189B1 (en) 2022-04-05
JP2018138551A (en) 2018-09-06
EP2897977A1 (en) 2015-07-29
JP2022169709A (en) 2022-11-09
MX2021006111A (en) 2021-07-07
AU2013320261A1 (en) 2015-04-09
EP3345923A1 (en) 2018-07-11
IN2015KN00657A (en) 2015-07-17
MX2015003644A (en) 2015-09-25
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
JP2015533806A (en) 2015-11-26
HK1208231A1 (en) 2016-02-26
US10913792B2 (en) 2021-02-09
EA201590359A1 (en) 2015-08-31
KR20220028177A (en) 2022-03-08
CA2884124A1 (en) 2014-03-27
AU2016250388A1 (en) 2016-11-17
KR20150056846A (en) 2015-05-27
PE20151079A1 (en) 2015-08-07
US20180230208A1 (en) 2018-08-16
MA37946A1 (en) 2018-01-31
CR20150153A (en) 2015-09-14
EP3916013A1 (en) 2021-12-01
IL237554A0 (en) 2015-04-30
CL2015000696A1 (en) 2015-10-23
BR112015006189A2 (en) 2019-11-26
US20210130451A1 (en) 2021-05-06
CN109999195A (en) 2019-07-12
US20150246969A1 (en) 2015-09-03
MA37946B1 (en) 2018-09-28
KR20230041086A (en) 2023-03-23
WO2014044768A1 (en) 2014-03-27
PH12015500591B1 (en) 2015-05-11
EA031489B1 (en) 2019-01-31
PH12015500591A1 (en) 2015-05-11
UA117228C2 (en) 2018-07-10
CN104995210A (en) 2015-10-21
AU2016250388B2 (en) 2018-07-19
CL2018000933A1 (en) 2018-07-20
IL237554B (en) 2019-12-31
DOP2015000070A (en) 2015-08-16

Similar Documents

Publication Publication Date Title
SG10201803778PA (en) Treatment for rheumatoid arthritis
MX342810B (en) Anti-il-6 receptor antibodies and methods of use.
UA113403C2 (en) METHOD OF IMPROVING THE EFFICIENCY OF FOLR1 CANCER THERAPY
HK1208151A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 182
NZ630542A (en) Methods of treating a tauopathy
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA112288C2 (en) Antibody forvulation and therapeutic regimens
MX356337B (en) Antibodies against human csf-1r and uses thereof.
MX367341B (en) TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE.
MX366405B (en) Use of long-acting glp-1 peptides.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
FI3791896T3 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2017003216A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients.
MY167233A (en) Il-17 antibody formulation
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
MD4615B1 (en) Isolated solid form of anamorelin monohydrochloride, pharmaceutical composition and method of making a pharmaceutical dosage form comprising it
MX2013003168A (en) Anti-ephrin-b2 antibody and use thereof.
MX2016011706A (en) Progesterone formulations.
MX2019008148A (en) Use of long-acting glp-1 peptides.
TN2013000265A1 (en) Anti-cd38 antibodies
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
UA72268U (en) Method for treating cognitive disorders with complex of low molecular polypeptide fractions (cortexin)